Gene test could match prostate cancer patients to better chemo

NCT ID NCT02955082

Ongoing Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether men with a certain type of advanced prostate cancer (castration-resistant) who have inherited DNA repair gene mutations respond better to the chemotherapy drug carboplatin. Researchers will first screen participants for these genetic changes, then treat those with mutations using carboplatin. The goal is to see if the tumors shrink or PSA levels drop, which could pave the way for more personalized cancer care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carboplatin (chemotherapy drug)
What this could lead to: If successful, this could show that genetic testing helps identify which men with advanced prostate cancer will benefit from carboplatin, leading to more personalized treatment.
What could go wrong: This is a small, early-phase study (Phase 2) with only 305 participants. The results may not apply to all patients, and carboplatin can cause side effects like low blood counts and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE REFRACTORY PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma hormone-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HORMONE REFRACTORY PROSTATE CANCER

Contacts and locations

Locations

Institute of Cancer Research and Royal Marsden Hospital

Sutton, Surrey, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.